Light-chain (AL) amyloidosis for nephrologists-treatment standard

被引：1

作者：

Anand, Shankara ^{[1
,2
,3
,4
]}

O'Neill-Dee, Maggie ^{[1
,2
,3
,5
]}

Sanchorawala, Vaishali ^{[1
,2
,3
]}

Verma, Ashish ^{[1
,2
,3
,6
]}

机构：

[1] Amyloidosis Ctr, Dept Med, Boston, MA 02118 USA

[2] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA 02118 USA

[3] Boston Med Ctr, Boston, MA 02118 USA

[4] Stanford Sch Med, Dept Med, Stanford, CA USA

[5] Massachusetts Gen Hosp, Dept Med, Boston, MA USA

[6] Boston Univ, Dept Med, Sect Nephrol USA4, Chobanian & Avedisian Sch Med, Boston, MA 02118 USA

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 40卷 / 01期

关键词：

AL amyloidosis; biomarker; chemotherapy; proteinuria; renal amyloidosis; STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; SYSTEMIC AMYLOIDOSIS; STAGING SYSTEM; HEPATIC AMYLOIDOSIS; TREATMENT OUTCOMES; RENAL-RESPONSE; PHASE; 1/2; DEXAMETHASONE; CYCLOPHOSPHAMIDE;

D O I：

10.1093/ndt/gfae224

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

Amyloidosis is a group of complex diseases caused by the misfolding and aggregation of proteins into amyloid fibrils. Light-chain (AL) amyloidosis is one of the most prevalent forms of amyloidosis, characterized by the gradual proliferation of light chains from plasma cell clones. A growing body of evidence has contributed to our understanding of its pathogenesis, presentation and clinical course. Increased recognition of its clinical sequelae has increased the prevalence of AL amyloidosis. Renal involvement, seen in up to 70% of cases, is particularly challenging due to its impact on quality of life and access to treatment options. Thus, early recognition of its unique sequelae, appropriate staging and a comprehensive understanding of treatment options balanced by their organ toxicities are crucial to managing this disease. We review the current treatment standards and discuss novel developments in the pathophysiology, diagnosis, outcome prediction and management of AL amyloidosis for the Nephrologist.

引用

页码：34 / 47

页数：14

共 50 条

[31] Systematic literature review of evidence in amyloid light-chain amyloidosis [J].

Lee, Charlene ;

Lam, Annette ;

Kangappaden, Teresa ;

Olver, Pyper ;

Kane, Sarah ;

Tran, Diana ;

Ammann, Eric .

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (06) :451-472

[32] Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy [J].

Cohen, Adam D. ;

Comenzo, Raymond L. .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, :287-294

[33] The Challenges in Chemotherapy and Stem Cell Transplantation for Light-Chain Amyloidosis [J].

Muchtar, Eli ;

Lin, Grace ;

Grogan, Martha .

CANADIAN JOURNAL OF CARDIOLOGY, 2020, 36 (03) :384-395

[34] Future directions in the clinical management of amyloid light-chain amyloidosis [J].

Haider, Sajjad ;

Ahmad, Nisar ;

Anaissie, Elias ;

Driscoll, James J. .

LEUKEMIA & LYMPHOMA, 2014, 55 (10) :2241-2251

[35] Diagnosis and management of systemic light chain AL amyloidosis [J].

Bhutani, Divaya ;

Lentzsch, Suzanne .

PHARMACOLOGY & THERAPEUTICS, 2020, 214

[36] A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis [J].

Ravichandran, Sriram ;

Mahmood, Shameem ;

Wisniowski, Brenden ;

Sachchithanantham, Sajitha ;

Popat, Rakesh ;

Lachmann, Helen ;

Rabin, Neil ;

Ramasamy, Karthik ;

Hawkins, Stephen ;

Kyriakou, Charalampia ;

Gillmore, Julian ;

Yong, Kwee ;

Hawkins, Philip ;

Jackson, Graham ;

Pratt, Guy ;

Wechalekar, Ashutosh D. .

BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) :328-332

[37] Treatment of Immunoglobulin Light Chain (Primary or AL) Amyloidosis [J].

Gertz, Morie A. ;

Buadi, Francis K. ;

Hayman, Suzanne R. .

ONCOLOGY-NEW YORK, 2011, 25 (07) :620-626

[38] The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis [J].

Nasr, Samih H. ;

Said, Samar M. ;

Valeri, Anthony M. ;

Sethi, Sanjeev ;

Fidler, Mary E. ;

Cornell, Lynn D. ;

Gertz, Morie A. ;

Dispenzieri, Angela ;

Buadi, Francis K. ;

Vrana, Julie A. ;

Theis, Jason D. ;

Dogan, Ahmet ;

Leung, Nelson .

KIDNEY INTERNATIONAL, 2013, 83 (03) :463-470

[39] Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis [J].

Kastritis, E. ;

Palladini, G. ;

Minnema, M. C. ;

Wechalekar, A. D. ;

Jaccard, A. ;

Lee, H. C. ;

Sanchorawala, V ;

Gibbs, S. ;

Mollee, P. ;

Venner, C. P. ;

Lu, J. ;

Schonland, S. ;

Gatt, M. E. ;

Suzuki, K. ;

Kim, K. ;

Cibeira, M. T. ;

Beksac, M. ;

Libby, E. ;

Valent, J. ;

Hungria, V ;

Wong, S. W. ;

Rosenzweig, M. ;

Bumma, N. ;

Huart, A. ;

Dimopoulos, M. A. ;

Bhutani, D. ;

Waxman, A. J. ;

Goodman, S. A. ;

Zonder, J. A. ;

Lam, S. ;

Song, K. ;

Hansen, T. ;

Manier, S. ;

Roeloffzen, W. ;

Jamroziak, K. ;

Kwok, F. ;

Shimazaki, C. ;

Kim, J-S ;

Crusoe, E. ;

Ahmadi, T. ;

Tran, N. P. ;

Qin, X. ;

Vasey, S. Y. ;

Tromp, B. ;

Schecter, J. M. ;

Weiss, B. M. ;

Zhuang, S. H. ;

Vermeulen, J. ;

Merlini, G. ;

Comenzo, R. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (01) :46-58

[40] Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone [J].

Kastritis, Efstathios ;

Dialoupi, Ioanna ;

Gavriatopoulou, Maria ;

Roussou, Maria ;

Kanellias, Nikolaos ;

Fotiou, Despina ;

Ntanasis-Stathopoulos, Ioannis ;

Papadopoulou, Elektra ;

Ziogas, Dimitrios C. ;

Stamatelopoulos, Kimon ;

Manios, Efstathios ;

Ntalianis, Argyrios ;

Eleutherakis-Papaiakovou, Evangelos ;

Papanikolaou, Asimina ;

Migkou, Magdalini ;

Papanota, Aristea-Maria ;

Gakiopoulou, Harikleia ;

Psimenou, Erasmia ;

Tselegkidi, Maria Irini ;

Tsitsilonis, Ourania ;

Kostopoulos, Ioannis ;

Terpos, Evangelos ;

Dimopoulos, Meletios A. .

BLOOD ADVANCES, 2019, 3 (20) :3002-3009

← 1 2 3 4 5 →